| Clinical laboratories are an essential part of the | | | | areas are taking full advantage of testing for |
| health industry. It is estimated that approximately | | | | early detection and disease prevention. Some of |
| 80% of physician's diagnoses are a result of | | | | the other issues and trends explored in this study |
| laboratory tests. The constant pressure to reduce | | | | include: |
| healthcare spending is shifting healthcare utilization | | | | • U.S. Demographics |
| in favor of the laboratory, making it an ever | | | | • Types of Specialty Tests |
| more valuable part of the treatment plan. As | | | | • Growing Competition |
| hospital stays are shortened, contact between | | | | • Increasing Life Expectancy |
| the physician and patient is reduced, which places | | | | • Growing Incidence of Disease |
| a larger role on labs to gather, interpret, and | | | | • New Product Offerings |
| deliver accurate information to the physician in a | | | | • Regulatory Environment |
| timely manner. We can expect to see an increase | | | | • Insurance and Reimbursement |
| in the number of clinical labs, particularly in the | | | | • Payer Types |
| independent sector, as these trends continue to | | | | • Developments in Personalized Medicine |
| influence the industry. | | | | A competitive analysis of leading clinical laboratory |
| Since the last time Kalorama Information studied | | | | providers includes: |
| this market two years ago, there have been | | | | • Quest Diagnostics, Inc. |
| substantial changes in the industry, including | | | | • Laboratory Corporation of America |
| changes in market share as major companies eat | | | | (LabCorp) |
| into regional labs, new competitors enter the | | | | • Genomic Health |
| marketplace, and new specialty tests are | | | | • Genoptix, Inc. |
| developed and priced. | | | | • Genzyme Corporation |
| Clinical Laboratory Services (Markets, Growth | | | | • DaVita |
| Opportunities, Competitive Analysis and | | | | • Clarient, Inc. |
| Competitor Profiles), provides an in-depth market | | | | • Spectra Laboratories |
| overview, a total market analysis, analysis by | | | | • Bio-Reference Laboratories |
| laboratory type, and by routine and specialty | | | | Our methodology: |
| testing and a review of the latest trends driving | | | | The information in this report is the result of |
| growth. Revenues and forecasts presented are | | | | interviews with executives and market experts, |
| for the U.S. market. Key international markets are | | | | as well as thorough research of secondary |
| discussed as well. | | | | sources such as company literature, trade |
| Key market data provided includes: | | | | publications and medical and business journals. The |
| • Hospital, Physician and Independent Lab | | | | emphasis Kalorama puts on primary research |
| Statistics | | | | guarantees that new insights will be uncovered |
| • Major Tests Performed by Clinical Lab | | | | that are not available from any other source. The |
| Companies | | | | most important part of Kalorama's efforts is its |
| • Disease Incidence and Trends Driving | | | | superior analysis of company activities and their |
| Lab Business | | | | true significance in the marketplace. |
| • Market Forecast to 2014 | | | | All market data pertains to the world market at |
| • Market Breakdown by Lab Type | | | | the manufacturers' level. The base year for data |
| (Hospital, Physician, Independent) | | | | was 2009. Historical data was provided for the |
| • Market Breakdown by Test Type | | | | years 2006, 2007 and 2008, with forecast data |
| (Specialty, Routine) | | | | provided for 2010 through 2014. Compound annual |
| • Market Share of Competitors | | | | growth rates (CAGRs) are provided for the |
| • Competitive Analysis of Leading clinical | | | | 2006-2009 and 2009-2014 periods for each |
| Lab Providers | | | | segment covered. A competitive analysis is |
| The issues and trends which are fueling growth: | | | | provided for the year 2009. The forecasted |
| A trend towards preventive and risk factor | | | | market analysis for 2010-2014 was largely based |
| testing has been noted in several disciplines, | | | | on demographic trends, new developments, |
| particularly in the areas of oncology, | | | | company performance trends, mergers and |
| endocrinology, and gynecology. Physicians in these | | | | acquisitions, and national expansion. |